<?xml version='1.0' encoding='utf-8'?>
<document id="19940026"><sentence text="In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies."><entity charOffset="68-76" id="DDI-PubMed.19940026.s1.e0" text="apixaban" /></sentence><sentence text="Apixaban is an oral, direct, and highly selective factor Xa inhibitor in late-stage clinical development for the prevention and treatment of thromboembolic diseases"><entity charOffset="0-8" id="DDI-PubMed.19940026.s2.e0" text="Apixaban" /></sentence><sentence text=" The metabolic drug-drug interaction potential of apixaban was evaluated in vitro"><entity charOffset="50-58" id="DDI-PubMed.19940026.s3.e0" text="apixaban" /></sentence><sentence text=" The compound did not show cytochrome P450 inhibition (IC(50) values &gt;20 microM) in incubations of human liver microsomes with the probe substrates of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5" /><sentence text=" Apixaban did not show any effect at concentrations up to 20 muM on enzyme activities or mRNA levels of selected P450 enzymes (CYP1A2, 2B6, and 3A4/5) that are sensitive to induction in incubations with primary human hepatocytes"><entity charOffset="1-9" id="DDI-PubMed.19940026.s5.e0" text="Apixaban" /></sentence><sentence text=" Apixaban showed a slow metabolic turnover in incubations of human liver microsomes with formation of O-demethylation (M2) and hydroxylation products (M4 and M7) as prominent in vitro metabolites"><entity charOffset="1-9" id="DDI-PubMed.19940026.s6.e0" text="Apixaban" /></sentence><sentence text=" Experiments with human cDNA-expressed P450 enzymes and P450 chemical inhibitors and correlation with P450 activities in individual human liver microsomes demonstrated that the oxidative metabolism of apixaban for formation of all metabolites was predominantly catalyzed by CYP3A4/5 with a minor contribution of CYP1A2 and CYP2J2 for formation of M2"><entity charOffset="201-209" id="DDI-PubMed.19940026.s7.e0" text="apixaban" /></sentence><sentence text=" The contribution of CYP2C8, 2C9, and 2C19 to metabolism of apixaban was less significant"><entity charOffset="60-68" id="DDI-PubMed.19940026.s8.e0" text="apixaban" /></sentence><sentence text=" In addition, a human absorption, distribution, metabolism, and excretion study showed that more than half of the dose was excreted as unchanged parent (f(m CYP) &lt;0" /><sentence text="5), thus significantly reducing the overall metabolic drug-drug interaction potential of apixaban"><entity charOffset="89-97" id="DDI-PubMed.19940026.s10.e0" text="apixaban" /></sentence><sentence text=" Together with a low clinical efficacious concentration and multiple clearance pathways, these results demonstrate that the metabolic drug-drug interaction potential between apixaban and coadministered drugs is low"><entity charOffset="174-182" id="DDI-PubMed.19940026.s11.e0" text="apixaban" /></sentence><sentence text="" /></document>